Zoetis reported Q2 2026 revenue of $2.5 billion, flat year-over-year and down 1% on an organic operational basis. Adjusted diluted earnings per share rose 4% to $1.87, whilst adjusted net income fell 2% to $781 million. The animal health company's global companion animal revenue declined 6% to $1.7 billion, with key dermatology products down 16% to $395 million. However, livestock revenue grew 11% to $731 million, driven by demand in cattle and poultry. International markets provided growth momentum, with revenue up 6% to $1.2 billion, whilst US revenue fell 7% to $1.3 billion. Companion animal diagnostics revenue increased 12% to $118 million. For full-year 2026, Zoetis expects revenue of $9.12 billion to $9.32 billion and adjusted diluted EPS of $6.15 to $6.25.

Zoetis names Saccaro CFO, chief operating officer. The basics: * Saccaro will join Zoetis as CFO, COO Aug. 17 * Newly created role includes oversight of manufacturing, supply operations * Current CFO will serve as special advisor to the CEO through early 2027 * Zoetis reported $2.5B in Q2 2026 revenue Zoetis Inc. has appointed James (Jay) Saccaro as executive vice president, chief financial officer and chief operating officer, effective Aug. 17, 2026. The Parsippany-headquartered animal health company announced the new hire Aug. 6. Zoetis also said it's a newly created position. Saccaro will take over responsibilities from Wetteny Joseph, who will remain with the company as a special advisor to CEO Kristin Peck until early 2027. According to Zoetis' executive team page, Joseph's title is executive vice president and CFO. Saccaro joins Zoetis from GE HealthCare, where he most recently served as vice president and CFO. At that company, Saccaro led initiatives across sectors such as finance, accounting, new product planning, R&D prioritization and capital allocation, according to Zoetis. Prior to GE HealthCare, Saccaro held various financial leadership positions at Baxter International Inc., Hillrom, Clear Channel Communications and The Walt Disney Co., according to his LinkedIn profile. New position. "We are excited to welcome Jay to Zoetis as we prepare for our next wave of innovation-driven growth," Peck said in a statement. "Jay brings a unique combination of skills to this newly created leadership position. He is a seasoned finance executive with 12 years of CFO experience at some of the world's leading healthcare companies and has proven expertise in successfully developing and executing company-wide strategic initiatives." Peck added that responsibilities of the expanded position will include: * Strengthening the company's global manufacturing and supply operations * Enhancing supply chain and distribution performance * Driving greater operational agility Saccaro said he was "thrilled to join the world's leading animal health company," adding that there was "tremendous runway to build on" Zoetis' legacy. "From the company's deep innovation pipeline to its products that have built and defined categories in the industry, Zoetis is an exceptional business grounded in a deep commitment to setting new standards for the future of animal care." 'A challenging quarter' Peck also thanked Joseph "for his strong leadership, partnership, and many important contributions since joining the company five years ago." In his final earnings update posted on LinkedIn Aug. 6, Joseph said, "I want to recognize our colleagues, who remained focused on delivering for our customers despite a challenging quarter." In the video, Joseph noted that "results this quarter fell short of our expectations," adding that, on an organic operational basis, Zoetis' revenue declined 1% and adjusted net income declined 2%. The company's quarterly report noted revenue of $2.5 billion for the second quarter of 2026. Breaking down results across its U.S. and international segments: * U.S. segment revenue: $1.3 billion, decreasing 7% relative to Q2 2025 * International segment revenue: $1.2 billion, increasing 8% on a reported basis and 6% on an organic operational basis compared with Q2 2025 Joseph said challenges such as declining veterinary visits and greater pet owner price sensitivity placed pressure on the companion animal industry. However, he said the company was "responding with urgency and focus." He added on the post, "I close this chapter with confidence in Zoetis' people, portfolio and pipeline. The work ahead is clear, and the company has the talent and capabilities to execute and create long-term value."

Zoetis cuts annual forecasts as pet healthcare demand slows. Aug 6 (Reuters) - Animal health company Zoetis cut its annual forecasts on Thursday after missing Wall Street estimates for second-quarter revenue, as softer demand for pet healthcare products and increased competition weighed. Shares of the company were down about 3% in premarket trading. - CEO Kristin Peck said lower clinic visits, pet owners' price sensitivity and heightened competition in key categories pressured the companion-animal market. - Zoetis cut its 2026 forecast for adjusted earnings per share to $6.15 to $6.25, compared with its prior view of $6.85 to $7.00. - The midpoint of the new forecast is below analysts' average estimate of $6.88, according to data compiled by LSEG. - The company also lowered its annual revenue forecast to between $9.12 billion and $9.32 billion, from $9.68 billion to $9.96 billion previously. - Peer IDEXX Laboratories on Tuesday raised its annual profit forecast after reporting better-than-expected quarterly results, helped by steady demand for pet health care diagnostics and higher testing volumes at veterinary clinics. - Quarterly revenue in Zoetis' companion-animal segment - its largest business - fell 5% to $1.71 billion, below analysts' estimate of $1.81 billion. - Second-quarter revenue was $2.47 billion, below analysts' estimates of $2.50 billion, while adjusted earnings of $1.87 per share slightly topped estimates of $1.86 per share, according to LSEG data. - Separately, Zoetis on Thursday also named former GE HealthCare CFO Jay Saccaro as chief financial officer and chief operating officer, effective August 17. Current CFO Wetteny Joseph will become a special adviser to the CEO until early 2027 to support the transition. (Reporting by Sahil Pandey in Bengaluru; Editing by Jonathan Ananda)